pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Jazz Pharmaceuticals plc ($JAZZ) · news · pharmadog
← back to Jazz Pharmaceuticals plc
News mentioning $JAZZ
19
stories
2d
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
biospace
6d
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
6d
STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism
stat
7d
STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
stat
8d
7 companies hiring in North Carolina now
biospace
8d
STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
stat
9d
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
stat
10d
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
biopharma dive
10d
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
10d
Jazz bets on epilepsy again by acquiring Actio for $820M upfront
endpoints
10d
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
stat
10d
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
fiercebiotech
17d
Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca
raps
22d
Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera
fiercebiotech
Jul 21, 26
The FDA’s 505(b)(2) pathway is an underestimated engine of value creation
biospace
Jun 17, 26
Jazz zeroes in on next-gen T cell engagers with AbCellera deal
biopharma dive
Jun 17, 26
Jazz turns to AbCellera for T cell engagers in up to $4.1B partnership
endpoints
Jun 15, 26
Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data
endpoints
Jun 12, 26
Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study
endpoints
